Depression research: where are we now?

Extensive studies have led to a variety of hypotheses for the molecular basis of depression and related mood disorders, but a definite pathogenic mechanism has yet to be defined. The monoamine hypothesis, in conjunction with the efficacy of antidepressants targeting monoamine systems, has long been the central topic of depression research. While it is widely embraced that the initiation of antidepressant efficacy may involve acute changes in monoamine systems, apparently, the focus of current research is moving toward molecular mechanisms that underlie long-lasting downstream changes in the brain after chronic antidepressant treatment, thereby reaching for a detailed view of the pathophysiology of depression and related mood disorders. In this minireview, we briefly summarize major themes in current approaches to understanding mood disorders focusing on molecular views of depression and antidepressant action.

[1]  J. Uslaner,et al.  Association of depressive symptoms during abstinence with the subjective high produced by cocaine. , 1999, The American journal of psychiatry.

[2]  B. Roth,et al.  Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression∗ ∗ See accompanying Editorial, in this issue. , 1999, Biological Psychiatry.

[3]  Margit Burmeister,et al.  A BDNF Coding Variant is Associated with the NEO Personality Inventory Domain Neuroticism, a Risk Factor for Depression , 2003, Neuropsychopharmacology.

[4]  P Riederer,et al.  Allelic Variation of Human Serotonin Transporter Gene Expression , 1996, Journal of neurochemistry.

[5]  Lei Yin,et al.  Nuclear Receptor Rev-erbα Is a Critical Lithium-Sensitive Component of the Circadian Clock , 2006, Science.

[6]  I. Heuser,et al.  Diurnal activity and pulsatility of the hypothalamus-pituitary-adrenal system in male depressed patients and healthy controls. , 1997, The Journal of clinical endocrinology and metabolism.

[7]  R. Duman,et al.  Antidepressant actions of the exercise-regulated gene VGF , 2007, Nature Medicine.

[8]  Rene Hen,et al.  Adult hippocampal neurogenesis in depression , 2007, Nature Neuroscience.

[9]  N. Martin,et al.  The relationship between stressful life events, the serotonin transporter (5-HTTLPR) genotype and major depression , 2005, Psychological Medicine.

[10]  A. Alterman,et al.  Reliability and validity of the Cocaine Selective Severity Assessment. , 1998, Addictive behaviors.

[11]  C. Duijn,et al.  A major SNP haplotype of the arginine vasopressin 1B receptor protects against recurrent major depression , 2003, Molecular Psychiatry.

[12]  K. Lesch,et al.  Association of Anxiety-Related Traits with a Polymorphism in the Serotonin Transporter Gene Regulatory Region , 1996, Science.

[13]  R. Solomon,et al.  An Opponent-Process Theory of Motivation , 1978 .

[14]  J. Nyengaard,et al.  Imipramine treatment increases the number of hippocampal synapses and neurons in a genetic animal model of depression , 2010, Hippocampus.

[15]  M. W. Young,et al.  Posttranscriptional and Posttranslational Regulation of Clock Genes , 2004, Journal of biological rhythms.

[16]  Jaime Fornaguera Trías,et al.  Factor analysis of Forced Swimming test, Sucrose Preference test and Open Field test on enriched, social and isolated reared rats , 2006, Behavioural Brain Research.

[17]  P. Gass,et al.  Reduced cell proliferation in the dentate gyrusis not correlated with the development of learned helplessness , 2003, Biological Psychiatry.

[18]  K. Wada,et al.  Enriched environments influence depression-related behavior in adult mice and the survival of newborn cells in their hippocampi , 2007, Behavioural Brain Research.

[19]  C. Spielewoy,et al.  Withdrawal from Chronic Phencyclidine Treatment Induces Long-Lasting Depression in Brain Reward Function , 2003, Neuropsychopharmacology.

[20]  Sung-jin Kim,et al.  Chronic mild stress decreases survival, but not proliferation, of new-born cells in adult rat hippocampus , 2006, Experimental & Molecular Medicine.

[21]  K. Brady,et al.  Mood Disorders and Substance Use Disorder: A Complex Comorbidity , 2005, Science & practice perspectives.

[22]  B. Pollock,et al.  Meta-analysis of serotonin transporter polymorphisms and affective disorders , 2004, Psychiatric genetics.

[23]  P. Hardin,et al.  Circadian rhythms from multiple oscillators: lessons from diverse organisms , 2005, Nature Reviews Genetics.

[24]  Fred H. Gage,et al.  Neurogenesis in the Adult Brain , 2002, The Journal of Neuroscience.

[25]  H. Manji,et al.  The Mood‐Stabilizing Agents Lithium and Valproate RobustlIncrease the Levels of the Neuroprotective Protein bcl‐2 in the CNS , 1999, Journal of neurochemistry.

[26]  J. Spiess,et al.  Suppression of the MEK/ERK signaling pathway reverses depression-like behaviors of CRF2-deficient mice , 2008, Neuropsychopharmacology.

[27]  D. Segal.  Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) , 2010 .

[28]  J. Takahashi,et al.  Regulation of dopaminergic transmission and cocaine reward by the Clock gene. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Gutman,et al.  The CRF1 receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal. , 2007, European journal of pharmacology.

[30]  F. Holloway,et al.  Alcohol's interactions with circadian rhythms. A focus on body temperature. , 2001 .

[31]  C. Ferris,et al.  Vasopressin antagonists as anxiolytics and antidepressants: recent developments. , 2008, Recent patents on CNS drug discovery.

[32]  Mikko Sairanen,et al.  Brain-Derived Neurotrophic Factor and Antidepressant Drugs Have Different But Coordinated Effects on Neuronal Turnover, Proliferation, and Survival in the Adult Dentate Gyrus , 2005, The Journal of Neuroscience.

[33]  K. Miyazaki,et al.  A Role for Glycogen Synthase Kinase-3β in the Mammalian Circadian Clock* , 2005, Journal of Biological Chemistry.

[34]  JaneR . Taylor,et al.  A comparison of the effects of clonidine and CNQX infusion into the locus coeruleus and the amygdala on naloxone-precipitated opiate withdrawal in the rat , 1998, Psychopharmacology.

[35]  Involvement of Acetylcholine in the Nucleus Accumbens in Cocaine Reinforcement , 1999, Annals of the New York Academy of Sciences.

[36]  Danielle L. Graham,et al.  Essential Role of BDNF in the Mesolimbic Dopamine Pathway in Social Defeat Stress , 2006, Science.

[37]  John H Krystal,et al.  Social supports and serotonin transporter gene moderate depression in maltreated children. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[38]  Barbara A. Sorg,et al.  Diurnal differences in dopamine transporter and tyrosine hydroxylase levels in rat brain: Dependence on the suprachiasmatic nucleus , 2007, Brain Research.

[39]  A. Phillips,et al.  A 'crash' course on psychostimulant withdrawal as a model of depression. , 2002, Trends in pharmacological sciences.

[40]  M. Candito,et al.  Circadian rhythms in depression and recovery: Evidence for blunted amplitude as the main chronobiological abnormality , 1989, Psychiatry Research.

[41]  M. Héry,et al.  Agomelatine, a New Antidepressant, Induces Regional Changes in Hippocampal Neurogenesis , 2006, Biological Psychiatry.

[42]  J. Seibyl,et al.  Elevated central serotonin transporter binding availability in acutely abstinent cocaine-dependent patients. , 2000, The American journal of psychiatry.

[43]  F. A. Schroeder,et al.  Antidepressant-Like Effects of the Histone Deacetylase Inhibitor, Sodium Butyrate, in the Mouse , 2007, Biological Psychiatry.

[44]  Keizo Takao,et al.  Abnormal social behavior, hyperactivity, impaired remote spatial memory, and increased D1-mediated dopaminergic signaling in neuronal nitric oxide synthase knockout mice , 2009, Molecular Brain.

[45]  H. Manji,et al.  The Mood‐Stabilizing Agent Valproate Inhibits the Activity of Glycogen Synthase Kinase‐3 , 2000, Journal of neurochemistry.

[46]  P. Riederer,et al.  Organization of the human serotonin transporter gene , 2005, Journal of Neural Transmission / General Section JNT.

[47]  R. Duman,et al.  A Neurotrophic Model for Stress-Related Mood Disorders , 2006, Biological Psychiatry.

[48]  René Hen,et al.  Hippocampal Neurogenesis: Regulation by Stress and Antidepressants , 2006, Biological Psychiatry.

[49]  H. Kleber,et al.  Abstinence symptomatology and psychiatric diagnosis in cocaine abusers. Clinical observations. , 1986, Archives of general psychiatry.

[50]  D. Knutson,et al.  Common problems in patients recovering from chemical dependency. , 2003, American family physician.

[51]  Edward V Nunes,et al.  Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. , 2004, JAMA.

[52]  A. Chagraoui,et al.  Agomelatine(S 20098) antagonizes the penile erections induced by the stimulation of 5-HT2C receptors in Wistar rats , 2003, Psychopharmacology.

[53]  E. Castrén,et al.  Co-Treatment with Diazepam Prevents the Effects of Fluoxetine on the Proliferation and Survival of Hippocampal Dentate Granule Cells , 2009, Biological Psychiatry.

[54]  Joseph E LeDoux,et al.  Contributions of the Amygdala to Emotion Processing: From Animal Models to Human Behavior , 2005, Neuron.

[55]  E. Nestler,et al.  Histone Modifications at Gene Promoter Regions in Rat Hippocampus after Acute and Chronic Electroconvulsive Seizures , 2004, The Journal of Neuroscience.

[56]  N. Risch,et al.  Interaction between the serotonin transporter gene (5-HTTLPR), stressful life events, and risk of depression: a meta-analysis. , 2009, JAMA.

[57]  M. Raichle,et al.  Subgenual prefrontal cortex abnormalities in mood disorders , 1997, Nature.

[58]  Johannes Lehtonen,et al.  Striatal dopamine transporter density in major depression , 1999, Psychopharmacology.

[59]  Y. Sheline.  Neuroimaging studies of mood disorder effects on the brain , 2003, Biological Psychiatry.

[60]  S. Hyman,et al.  Initiation and adaptation: a paradigm for understanding psychotropic drug action. , 1996, The American journal of psychiatry.

[61]  E. Herzog,et al.  Lithium lengthens the circadian period of individual suprachiasmatic nucleus neurons , 2000, Neuroreport.

[62]  M. Millan,et al.  The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways , 2003, Journal of Pharmacology and Experimental Therapeutics.

[63]  Jon T. Willie,et al.  To eat or to sleep? Orexin in the regulation of feeding and wakefulness. , 2001, Annual review of neuroscience.

[64]  Linda Carpenter,et al.  Reduced brain serotonin transporter availability in major depression as measured by [123I]-2β-carbomethoxy-3β-(4-iodophenyl)tropane and single photon emission computed tomography , 1998, Biological Psychiatry.

[65]  Sang Ki Park,et al.  Par-4 Links Dopamine Signaling and Depression , 2005, Cell.

[66]  S. Kapur,et al.  Effects of catecholamine depletion on D2 receptor binding, mood, and attentiveness in humans: a replication study , 2003, Pharmacology Biochemistry and Behavior.

[67]  R. Solomon,et al.  An opponent-process theory of motivation. I. Temporal dynamics of affect. , 1974, Psychological review.

[68]  Eric J. Nestler,et al.  Epigenetic regulation in psychiatric disorders , 2007, Nature Reviews Neuroscience.

[69]  Andrew H. Miller,et al.  When Not Enough Is Too Much: The Role of Insufficient Glucocorticoid Signaling in the Pathophysiology of Stress-Related Disorders , 2003 .

[70]  H. Manji,et al.  Endophenotypes in bipolar disorder. , 2002, American journal of medical genetics.

[71]  J. Mill,et al.  Molecular studies of major depressive disorder: the epigenetic perspective , 2007, Molecular Psychiatry.

[72]  K. Lesch,et al.  Serotonin transporter gene polymorphism and affective disorder , 1996, The Lancet.

[73]  P. Muglia,et al.  The brain-derived neurotrophic factor gene confers susceptibility to bipolar disorder: evidence from a family-based association study. , 2002, American journal of human genetics.

[74]  C. Coffey,et al.  Quantitative cerebral anatomy in depression. A controlled magnetic resonance imaging study. , 1993, Archives of general psychiatry.

[75]  D. Morilak,et al.  Antidepressants and brain monoaminergic systems: a dimensional approach to understanding their behavioural effects in depression and anxiety disorders. , 2004, The international journal of neuropsychopharmacology.

[76]  E. Castrén,et al.  Activation of the TrkB Neurotrophin Receptor Is Induced by Antidepressant Drugs and Is Required for Antidepressant-Induced Behavioral Effects , 2003, The Journal of Neuroscience.

[77]  Gudrun Ahnert-Hilger,et al.  Regulation of Monoamine Oxidase A by Circadian-Clock Components Implies Clock Influence on Mood , 2008, Current Biology.

[78]  B. Zörner,et al.  Forebrain-specific trkB-receptor knockout mice: behaviorally more hyperactive than “depressive” , 2003, Biological Psychiatry.

[79]  G. Goodwin,et al.  Polymorphism in serotonin transporter gene associated with susceptibility to major depression , 1996, The Lancet.

[80]  K. Ressler,et al.  Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders , 2000, Depression and anxiety.

[81]  R. Hen,et al.  Requirement of Hippocampal Neurogenesis for the Behavioral Effects of Antidepressants , 2003, Science.

[82]  Guanghua Xiao,et al.  Imipramine Treatment and Resiliency Exhibit Similar Chromatin Regulation in the Mouse Nucleus Accumbens in Depression Models , 2009, The Journal of Neuroscience.

[83]  Rhythm and blues: the theory and treatment of seasonal affective disorder. , 1996, The British journal of clinical psychology.

[84]  Florian Holsboer,et al.  The Corticosteroid Receptor Hypothesis of Depression , 2000, Neuropsychopharmacology.

[85]  D B Boivin,et al.  Influence of sleep-wake and circadian rhythm disturbances in psychiatric disorders. , 2000, Journal of psychiatry & neuroscience : JPN.

[86]  D. Kripke,et al.  Autorhythmometry in manic-depressives. , 1975, Chronobiologia.

[87]  C. Belzung,et al.  Involvement of vasopressin in affective disorders. , 2008, European journal of pharmacology.

[88]  Andrew H. Miller,et al.  When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. , 2011, The American journal of psychiatry.

[89]  Glenda M MacQueen,et al.  Course of illness, hippocampal function, and hippocampal volume in major depression , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[90]  F. Holloway,et al.  Alcohol’s Interactions With Circadian Rhythms , 2001, Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism.

[91]  J. Price,et al.  Prefrontal cortical projections to the hypothalamus in Macaque monkeys , 1998, The Journal of comparative neurology.

[92]  W. Drevets,et al.  The cellular neurobiology of depression , 2001, Nature Medicine.

[93]  S. Givre.  Gage FH. Neurogenesis in the adult brain. , 2003 .

[94]  R. Belmaker,et al.  Major depressive disorder. , 2008, The New England journal of medicine.

[95]  F. Gage,et al.  More hippocampal neurons in adult mice living in an enriched environment , 1997, Nature.

[96]  R. Duman,et al.  Brain-Derived Neurotrophic Factor Produces Antidepressant Effects in Behavioral Models of Depression , 2002, The Journal of Neuroscience.

[97]  Kole T. Roybal,et al.  Mania-like behavior induced by disruption of CLOCK , 2007, Proceedings of the National Academy of Sciences.

[98]  Arthur W Toga,et al.  Anterior cingulate, gyrus rectus, and orbitofrontal abnormalities in elderly depressed patients: an MRI-based parcellation of the prefrontal cortex. , 2004, The American journal of psychiatry.

[99]  E. Mocaer,et al.  Entrainment of circadian rhythms by S-20098, a melatonin agonist, is dose and plasma concentration dependent , 1996, Pharmacology Biochemistry and Behavior.

[100]  S. Reppert,et al.  Molecular analysis of mammalian circadian rhythms. , 2001, Annual review of physiology.

[101]  J. Honour,et al.  Hypothalamic-pituitary-adrenal axis. , 1994, Respiratory medicine.

[102]  J. Takahashi,et al.  Mammalian circadian biology: elucidating genome-wide levels of temporal organization. , 2004, Annual review of genomics and human genetics.

[103]  E. Nestler,et al.  The Mesolimbic Dopamine Reward Circuit in Depression , 2006, Biological Psychiatry.

[104]  Z. Marinova,et al.  The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons , 2009, Molecular Psychiatry.

[105]  Z. Marinova,et al.  Synergistic Neuroprotective Effects of Lithium and Valproic Acid or Other Histone Deacetylase Inhibitors in Neurons: Roles of Glycogen Synthase Kinase-3 Inhibition , 2008, The Journal of Neuroscience.

[106]  J. John Mann,et al.  Antidepressants increase neural progenitor cells in the human hippocampus , 2009, Neuropsychopharmacology.

[107]  Y. Sheline.  3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity , 2000, Biological Psychiatry.

[108]  D. Chuang,et al.  Histone Deacetylase Inhibitors Exhibit Anti-Inflammatory and Neuroprotective Effects in a Rat Permanent Ischemic Model of Stroke: Multiple Mechanisms of Action , 2007, Journal of Pharmacology and Experimental Therapeutics.

[109]  R. Hen,et al.  Drug-Dependent Requirement of Hippocampal Neurogenesis in a Model of Depression and of Antidepressant Reversal , 2008, Biological Psychiatry.

[110]  G. Valdez.  CRF receptors as a potential target in the development of novel pharmacotherapies for depression. , 2009, Current pharmaceutical design.

[111]  G. Werstuck,et al.  Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3 , 2005, Journal of Cell Science.

[112]  J. Macher,et al.  Serotonin transporter (5-HTT) gene polymorphisms are not associated with susceptibility to mood disorders. , 1998, American journal of medical genetics.

[113]  C. Allis,et al.  Translating the Histone Code , 2001, Science.

[114]  E. Cadenas,et al.  Physiology and Neurobiology of Stress and Adaptation: Central Role of the Brain , 2007 .

[115]  Michael X. Cohen,et al.  Deep Brain Stimulation to Reward Circuitry Alleviates Anhedonia in Refractory Major Depression , 2008, Neuropsychopharmacology.

[116]  C. Pittenger,et al.  Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms , 2008, Neuropsychopharmacology.

[117]  G. Koob.  Animal models of craving for ethanol. , 2000, Addiction.

[118]  R. Jope.  Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes. , 2003, Trends in pharmacological sciences.

[119]  W. Drevets.  Neuroimaging and neuropathological studies of depression: implications for the cognitive-emotional features of mood disorders , 2001, Current Opinion in Neurobiology.

[120]  B. McEwen,et al.  Association of depression with medical illness: does cortisol play a role? , 2004, Biological Psychiatry.

[121]  A. Caspi,et al.  Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene , 2003, Science.

[122]  Serge Nef,et al.  Brain-Derived Neurotrophic Factor Conditional Knockouts Show Gender Differences in Depression-Related Behaviors , 2007, Biological Psychiatry.

[123]  M. Millan,et al.  Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade , 2005, Psychopharmacology.

[124]  G. Flügge,et al.  CRE/CREB-Driven Up-Regulation of Gene Expression by Chronic Social Stress in CRE-Luciferase Transgenic Mice: Reversal by Antidepressant Treatment , 2007, PloS one.

[125]  K. J. Parker,et al.  Neuroendocrine aspects of hypercortisolism in major depression , 2003, Hormones and Behavior.

[126]  J. Redman,et al.  Dose dependent effects of S-20098, a melatonin agonist, on direction of re-entrainment of rat circadian activity rhythms , 1995, Psychopharmacology.

[127]  E. Nestler,et al.  Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action , 2006, Nature Neuroscience.

[128]  H. Manev,et al.  Dopamine receptor-mediated regulation of neuronal “clock” gene expression , 2009, Neuroscience.

[129]  F. Holsboer,et al.  Stress and the brain: from adaptation to disease , 2005, Nature Reviews Neuroscience.

[130]  Olga V. Demler,et al.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. , 2005, Archives of general psychiatry.

[131]  Walter Ling,et al.  Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. , 2004, Archives of general psychiatry.

[132]  C. Nemeroff,et al.  Psychoneuroendocrinology of depression. Hypothalamic-pituitary-adrenal axis. , 1998, The Psychiatric clinics of North America.

[133]  M. Burmeister.  Basic concepts in the study of diseases with complex genetics , 1999, Biological Psychiatry.

[134]  J. Blendy.  The Role of CREB in Depression and Antidepressant Treatment , 2006, Biological Psychiatry.

[135]  M. Schwald,et al.  Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. , 2005, Brain research. Molecular brain research.

[136]  A. Lozano,et al.  Deep Brain Stimulation for Treatment-Resistant Depression , 2005, Neuron.

[137]  D. Caprioli,et al.  Social isolation selectively reduces hippocampal brain-derived neurotrophic factor without altering plasma corticosterone , 2006, Behavioural Brain Research.